Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.70 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 3/20 | 0.51 |
| ▸ | GFER | P55789 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | DRD2 | P14416 | 4/20 | 0.48 |
| ▸ | DRD4 | P21917 | 4/20 | 0.48 |
| ▸ | DRD3 | P35462 | 4/20 | 0.48 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.48 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.48 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.48 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30293223 | 1.00 | HPGD (0.70) | HPGDMEN1KMT2APOLBGAA | |
| Hydrochloric Acid SCHEMBL30293267 | 0.98 | HPGD (0.68) | HPGDMEN1KMT2APOLBGAA | |
| SCHEMBL9627340 | 0.89 | HPGD (0.66) | HPGDMEN1KMT2APOLBGAA | |
| SCHEMBL11692973 | 0.86 | KMT2A (0.56) | HPGDMEN1KMT2APOLBGAA | |
| SCHEMBL5215688 | 0.86 | HPGD (0.53) | HPGDMEN1KMT2APOLBGAA | |
| SCHEMBL13167920 | 0.86 | HPGD (0.53) | HPGDMEN1KMT2APOLBALDH1A1 | |
| SCHEMBL7290201 | 0.86 | HPGD (0.53) | HPGDMEN1KMT2APOLBGAA | |
| SCHEMBL14281334 | 0.86 | HPGD (0.59) | HPGDMEN1KMT2APOLBGAA | |
| SCHEMBL7287582 | 0.85 | CA12 (0.68) | HPGDMEN1KMT2APOLBGAA | |
| Hydrochloric Acid SCHEMBL7288973 | 0.84 | CA12 (0.66) | HPGDMEN1KMT2APOLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1317013-B1 | NON-AQUEOUS ELECTROLYTE AND SECONDARY CELL USING THE SAME | MITSUBISHI CHEM CORP (JP) | 2017-03-15 | — | — | EP | disclosed |
| EP-1622874-B1 | 3,4-DIHYDRO-1H-QUINOLIN-2-ONE DERIVATIVES AS NOREPINEPHRINE REUPTAKE INHIBITORS | LILLY CO ELI (US) | 2007-10-03 | — | — | EP | disclosed |
| US-20070105845-A1 | Quinolone derivatives | ELI LILLY AND COMPANY PATENT DIVISION (US) | 2007-05-10 | — | — | US | disclosed |
| US-20070105960-A1 | Treatment of learning disabilities and motor skills disorder with norepinephrine reuptake inhibitors | ELI LILLY AND COMPANY (US) | 2007-05-10 | — | — | US | disclosed |
| US-20070032554-A1 | Treatment of stuttering and other communication disorders with norepinephrine reuptake inhibitors | ELILILLY AND COMPANY A CORPORATION | 2007-02-08 | — | — | US | disclosed |
| US-20070015786-A1 | Treatment of hot flashes, impulse control disorders and personality change due to a general medical condition | ELI LILY AND COMPANY (US) | 2007-01-18 | — | — | US | disclosed |
| US-20060241188-A1 | Treatment of pervasive developemental disorders with norepinephrine reuptake inhibitors | ELILILLY AND COMPANY (US) | 2006-10-26 | — | — | US | disclosed |
| US-6942948-B2 | Nonaqueous electrolyte solution and secondary battery employing the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2005-09-13 | — | — | US | disclosed |
| CN-1215595-C | Nonaqueous electrolyte and secondary battery using the same | MITSUBISHI CHEM CORP (JP) | 2005-08-17 | — | — | CN | disclosed |
| WO-2005053663-A2 | NOREPINEPHRINE REUPTAKE INHIBITORS USEFUL FOR TREATMENT OF COGNITIVE FAILURE | ELI LILLY AND COMPANY (US) | 2005-06-16 | — | — | WO | disclosed |
| CN-1465117-A | Nonaqueous electrolyte and secondary battery using the same | MITSUBISHI CHEM CORP (JP) | 2003-12-31 | — | — | CN | disclosed |
| US-20030165733-A1 | Nonaqueous electrolyte solution and secondary battery employing the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2003-09-04 | — | — | US | disclosed |
| EP-1317013-A1 | NON-AQUEOUS ELECTROLYTE AND SECONDARY CELL USING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2003-06-04 | — | — | EP | disclosed |
| US-5434148-A | β-carboline derivative | TANABE SEIYAKU CO., LTD. (JP) | 1995-07-18 | — | — | US | disclosed |
| EP-0572235-A2 | Beta-carboline derivatives with anticholecystoquinine activity | TANABE SEIYAKU CO., LTD. (JP) | 1993-12-01 | — | — | EP | disclosed |
| US-4058532-A | 1-Phenyl-3,4-dihydrocarbostyrils | STERLING DRUG INC. (US) | 1977-11-15 | — | — | US | disclosed |
| US-4058532-A | 1-Phenyl-3,4-dihydrocarbostyrils | STERLING DRUG INC. (US) | 1977-11-15 | — | — | US | disclosed |
| US-4049715-A | 3-[2-(4-Anisidino)phenyl]-1-phenyl-1-propiophenones and propanols | STERLING DRUG INC. (US) | 1977-09-20 | — | — | US | disclosed |
| US-3994902-A | Certain 1,2-diphenyl-1,2,3,4-tetrahydroquinoline compounds | STERLING DRUG INC. (US) | 1976-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105845-A1 | Quinolone derivatives | NQO2, NQO1, RECQL | HPGD 539/4885MEN1 694/4885KMT2A 2950/4885 |
| US-20060241188-A1 | Treatment of pervasive developemental disorders with norepinephrine reuptake inhibitors | SLC6A2, SLC6A3, SLC6A4 | HPGD 1162/4885MEN1 2755/4885KMT2A 647/4885 |
| US-20070105960-A1 | Treatment of learning disabilities and motor skills disorder with norepinephrine reuptake inhibitors | SLC6A2, SLC6A3, SLC6A4 | HPGD 1770/4885MEN1 4612/4885KMT2A 565/4885 |
| US-20070032554-A1 | Treatment of stuttering and other communication disorders with norepinephrine reuptake inhibitors | SLC6A2, SLC6A4, SLC6A3 | HPGD 713/4885MEN1 2243/4885KMT2A 2954/4885 |
| US-20070015786-A1 | Treatment of hot flashes, impulse control disorders and personality change due to a general medical condition | SLC6A2, SLC6A4, HTR5A | HPGD 271/4885MEN1 237/4885KMT2A 2399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.